[{"id":"b45c95c1-91da-4ed1-82bd-d94f9d53ddec","acronym":"","url":"https://clinicaltrials.gov/study/NCT02283320","created_at":"2021-01-18T10:45:27.234Z","updated_at":"2024-07-02T16:37:32.711Z","phase":"Phase 2","brief_title":"A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02283320","lead_sponsor":"BIND Therapeutics","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • PSMA-targeted docetaxel (BIND-014)"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2016-04-18"}]